Mylan tells investor King deal will boost profits
609796
Despite concerns raised by an investor, Mylan Laboratories Inc. reaffirmed that its proposed acquisition of generic drug maker King Pharmaceuticals Inc.
205093
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) on Monday said its board does not believe discussions with financier Carl Icahn&#39;s about his unsolicited proposal to buy the company are in the company&#39;s best interests.
146318
PITTSBURGH, Dec. 20 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of $.03 per share will be payable on January 14, 2005, to shareholders
639540
PITTSBURGH Carl Icahn, the largest shareholder of Mylan Laboratories, is now threatening to push for new company directors to stop the generic drug maker&#39;s four (B) billion-dollar takeover bid of King Pharmaceuticals.
67468
LONDON/AMSTERDAM  - The takeover battle for ABN AMRO  heated up on Monday with the Royal Bank of Scotland  consortium boosting the cash element of its 71.1 billion-euro ($98 billion) offer.
282450
Mylan Laboratories Inc., the biggest US maker of generic drugs, received a $20-a-share bid from Carl Icahn, the company&#39;s largest investor and a critic of Mylan&#39;s plan to buy King Pharmaceuticals Inc.
588024
Financier Carl Icahn on Friday offered to buy the shares of generic drugmaker Mylan Laboratories  that he does not already own for &#36;4.9 billion, or &#36;20 a share, according to a government filing.
191627
Check--or checkmate? Carl Icahn, attempting to block Mylan Laboratories (nyse: MYL - news - people ) in its buyup of King Pharmaceuticals (nyse: KG - news - people ), made his move: Earlier this month, the
447104
British billionaire adds to stake even after a big-fourth-quarter loss.
166080
Company's recent acquisition will improve its competitive advantages.
386076
In a letter to the board of directors at Mylan Laboratories (nyse: MYL - news - people ), financier Carl Icahn questioned their silence on the recent financial restatements by King Pharmaceuticals (nyse: KG - news - people ), calling the &quot;lack of
226932
Billionaire financier Carl Icahn offered to buy Mylan Laboratories Inc., the largest US maker of generic medicines, for about $5.38 billion to block Mylan&#39;s proposed purchase of King Pharmaceuticals Inc.
357770
Veteran financier Carl Icahn said he and a group of investors are willing to buy Mylan Laboratories Inc. for $20 per share, according to a Friday filing with the Securities and Exchange Commission.
411592
It makes sense for the drugmaker to sell millions more shares right now.
292602
Drugmaker Mylan Laboratories Inc.  posted a quarterly loss on Thursday on charges related to an acquisition, but reported adjusted profit that beat its previous forecast helped by sales of generic drugs for pain and bladder control.
321927
Mylan Laboratories&#39; (MYL:NYSE - news - research) board of directors Monday once again rejected investor Carl Icahn&#39;s takeover offer while also questioning his intentions and said it planned to go ahead with its planned acquisition of King Pharmaceuticals
109550
Mylan Laboratories Inc.MYL.N on  Wednesday said it was unlikely to complete its $3.4 billion  acquisition of King Pharmaceuticals Inc.KG.N at the current  price because of King's need to restate earnings.